primidone has been researched along with Convulsions, Grand Mal in 72 studies
Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.
primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.
Excerpt | Relevance | Reference |
---|---|---|
"Cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and probenecid were examined in 14 children with epilepsy (ages 6 months to 17 years) and 17 controls (ages 14 months to 16 years)." | 7.65 | Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. ( Bowers, MB; Cohen, DJ; Shaywitz, BA, 1975) |
" Serum concentrations differed even with the same dosage among individual dogs." | 5.28 | [Effectiveness of bromide in therapy resistant epilepsy of dogs]. ( Jürgens, U; Schwartz-Porsche, D, 1991) |
"Cerebrospinal fluid (CSF) concentrations of 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and probenecid were examined in 14 children with epilepsy (ages 6 months to 17 years) and 17 controls (ages 14 months to 16 years)." | 3.65 | Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. ( Bowers, MB; Cohen, DJ; Shaywitz, BA, 1975) |
" Phenobarbital is usually given as well to prevent grand mal seizures." | 3.64 | Treatment of epilepsy. ( BAILEY, AA, 1963) |
"The treatment with primidone alone of 53 epileptic patients with generalized tonic-clonic seizures, partial attacks with elementary symptomatology, and partial fits with complex symptomatology removed them completely in 75, 64." | 2.67 | [Therapeutic and pharmacological monitoring of individual monotherapy of epilepsy with hexamidine]. ( Gromov, SA; Gusel', VA; Khorshev, SK; Smirnov, DP, 1991) |
" Serum concentrations differed even with the same dosage among individual dogs." | 1.28 | [Effectiveness of bromide in therapy resistant epilepsy of dogs]. ( Jürgens, U; Schwartz-Porsche, D, 1991) |
"Only when the epilepsy is uncontrolled despite high plasma concentrations which cannot be raised because of side effects, a second drug should be given." | 1.27 | [Pharmacotherapy of epilepsy--current problems and controversies]. ( Schmidt, D, 1983) |
"gamma-Aminobutyric acid (GABA) levels were determined in cisternal cerebrospinal fluid (CSF) of 19 epileptic dogs with generalized tonic-clonic (grand mal) seizures using a radioreceptor assay." | 1.27 | Low levels of gamma-aminobutyric acid in cerebrospinal fluid of dogs with epilepsy. ( Löscher, W; Schwartz-Porsche, D, 1986) |
"Phenytoin serum concentrations in 115 epileptics treated on an inpatient basis showed, in two groups, only relatively weak correlation with the dosage used." | 1.26 | [Clinical significance of serum phenytoin level]. ( Oettinger, B; Richter, K, 1978) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 69 (95.83) | 18.7374 |
1990's | 3 (4.17) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
COUSTON, TA | 1 |
RUDOLF G DE, M | 1 |
BAILEY, AA | 1 |
LIVINGSTON, S | 3 |
TORRES, IC | 1 |
DOBER, B | 1 |
GIBBS, FA | 1 |
RICH, CL | 1 |
GIBBS, EL | 1 |
WHITTY, CW | 1 |
LISHMAN, WA | 1 |
FITZGIBBON, JP | 1 |
JONGMANS, JW | 1 |
LORGE, M | 1 |
GASTAUT, H | 1 |
Schmidt, D | 1 |
Forsythe, WI | 1 |
Sills, MA | 1 |
Quednow, B | 1 |
Walther, H | 1 |
Reynolds, EH | 3 |
Shorvon, SD | 1 |
Thibodeau, LG | 1 |
Ferrera, PC | 1 |
Wutke, K | 1 |
Müller, E | 1 |
Dittrich, P | 1 |
Chadwick, D | 1 |
Galbraith, AW | 1 |
Müller-Jensen, A | 1 |
Hagenah, R | 1 |
Matz, DR | 1 |
Rolf, LH | 1 |
Brune, GG | 1 |
Oettinger, B | 1 |
Richter, K | 1 |
Deisenhammer, E | 2 |
Sommer, R | 1 |
Borgheresi, S | 1 |
Luti, E | 1 |
Mecherini, L | 1 |
Buti Cossi, D | 1 |
Bardini, MR | 1 |
Shaywitz, BA | 1 |
Cohen, DJ | 1 |
Bowers, MB | 1 |
Ferry, DG | 1 |
Ferry, D | 1 |
McQueen, EG | 1 |
Richens, A | 1 |
Doose, H | 2 |
Schwartz, I | 1 |
Rodin, EA | 1 |
Rim, CS | 1 |
Kitano, H | 1 |
Lewis, R | 1 |
Rennick, PM | 1 |
Goodman, RM | 1 |
Katznelson, MB | 1 |
Hertz, M | 1 |
Katznelson, D | 1 |
Rotem, Y | 1 |
Thomas, JA | 1 |
Knotts, GR | 1 |
Gromov, SA | 1 |
Gusel', VA | 1 |
Khorshev, SK | 1 |
Smirnov, DP | 1 |
Schwartz-Porsche, D | 2 |
Jürgens, U | 1 |
Löscher, W | 1 |
Frey, HH | 1 |
Steidl, L | 1 |
Tolde, I | 1 |
Svomová, V | 1 |
Coulter, DL | 1 |
Stefan, H | 1 |
Falconer, MA | 1 |
Davidson, S | 1 |
Sibley, WA | 1 |
Parsonage, M | 1 |
Afifi, AK | 1 |
Van Allen, MW | 1 |
Schütze, I | 1 |
Salomon, B | 1 |
Thal, W | 1 |
Völzke, E | 1 |
Meyer, JG | 1 |
Leonidas, JC | 1 |
Brill, PW | 1 |
Waldman, N | 1 |
Billinghurst, JR | 1 |
German, GA | 1 |
Orley, JH | 1 |
Christiansen, C | 1 |
Rodbro, P | 1 |
Sjö, O | 1 |
Waltl, H | 1 |
Mitterstieler, G | 1 |
Schwingshackl, A | 1 |
Huang, CY | 1 |
McLeod, JG | 1 |
Sampson, D | 1 |
Hensley, WJ | 1 |
Saper, JR | 1 |
Lossing, JH | 1 |
Millichap, JG | 1 |
Lücking, T | 1 |
Delling, G | 1 |
Villamater, C | 1 |
Sakata, Y | 1 |
Gibberd, FB | 1 |
Wilson, J | 1 |
Jannasch, R | 1 |
Ritter, G | 1 |
Travers, RD | 1 |
Gallagher, BB | 3 |
Baumel, IP | 2 |
Mattson, RH | 2 |
Horne, PD | 1 |
Gudmundsson, G | 1 |
Langlands, AO | 1 |
Maclean, N | 1 |
Pearson, JG | 1 |
Williamson, ER | 1 |
Matthes, A | 1 |
Olesen, OV | 1 |
Dam, M | 1 |
Milichap, JG | 1 |
Aymat, F | 1 |
Roth, G | 1 |
Rett, A | 1 |
Frühmann, E | 1 |
Haub, G | 1 |
Auert, G | 1 |
Bechthold, HG | 1 |
Schottky, A | 1 |
Borkowska, Z | 1 |
Mazurkowa, K | 1 |
Wojakowski, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
An Open-Label Treatment of ZX008 (Fenfluramine Hydrochloride) in Pediatric and Adult Epilepsy Patients (Ages 4-25) With Sunflower Syndrome.[NCT03790137] | Phase 3 | 20 participants (Actual) | Interventional | 2019-05-31 | Active, not recruiting | ||
Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy[NCT03475225] | Phase 3 | 400 participants (Anticipated) | Interventional | 2018-04-30 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The number of handwaving episodes (seizures) per day were recorded on a seizure diary by either the subject or the parent of the subject. One handwaving episode was defined as the period starting from when the hand first came up toward the face, until there was a brief pause in waving. Subjects and their caregivers were instructed to record the total number of handwaving episodes each day during a one month baseline, and during the 3 month treatment period.~The baseline seizure frequency was calculated as an average of the reported handwaving episodes per day during the baseline period. This number was compared to the average episodes per day for the final month of the study (month 3 of treatment with fenfluramine) for each patient. The median percent change in frequency of handwaving episodes across all patients is reported below." (NCT03790137)
Timeframe: Month 3
Intervention | % change in hand waving episodes (Median) |
---|---|
Treatment Group | -66.2 |
Daily seizure logs will be maintained by either the subject or the parent of the subject and used to calculate seizure frequency. Frequency of Generalized Tonic-clonic seizures was recorded as an average number of seizures/day. The average number of tonic-clonic seizures per day during the baseline period was compared to the average number of tonic-clonic seizures per day during the final month (month 3) for each patient that had experienced at least one tonic-clonic seizure in their lifetime. (NCT03790137)
Timeframe: Month 3
Intervention | tonic-clonic seizures/day (Mean) |
---|---|
Treatment Group | 0 |
The investigators will read and interpret pre-drug (baseline) and post-drug EEGs (month 3 of core study) for the first 9 patients. The average number of spikes/hour across these patients will be reported for both pre- and post-treatment EEGs. (NCT03790137)
Timeframe: Month 3
Intervention | spikes/hour (Mean) | |
---|---|---|
Pre-Treatment | Post-Treatment | |
Treatment Group | 73.9 | 50.4 |
"The Beck Self Report Inventory will be administered at baseline, and 84 days after the first dose (Month 3; Visit 5). This questionnaire assesses self-concept, depression, anxiety, anger and disruptive behavior through a 100-item self-report.~The raw scores for subscales are calculated in the following manner:~Add scores from Items 1-20 for the total Beck Self Concept Inventory for Youth (BSCI-Y) score.~Add scores from Items 21-40 for the total Beck Anxiety Inventory for Youth (BAI-Y) score.~Add scores from Items 41-60 for the total Beck Depression Inventory for Youth (BDI-Y) score.~Add scores from Items 61-80 for the total Beck Anger Inventory for Youth (BANI-Y) score.~Add scores from Items 81-100 for the total Beck Disruptive Inventory for Youth (BDBI-Y) score.~Raw scores will be translated into T-scores.~T-scores for BYI are as follows:~55 or less = average~55-59 = mildly elevated~60-69 = moderately elevated~70+ = extremely elevated" (NCT03790137)
Timeframe: Month 3
Intervention | T score (Mean) | |
---|---|---|
Baseline Score | Month 3 Score | |
Treatment Group | 45.00 | 41.75 |
"The Beck Self Report Inventory will be administered at baseline, and 84 days after the first dose (Month 3; Visit 5). This questionnaire assesses self-concept, depression, anxiety, anger and disruptive behavior through a 100-item self-report.~The raw scores for subscales are calculated in the following manner:~Add scores from Items 1-20 for the total Beck Self Concept Inventory for Youth (BSCI-Y) score.~Add scores from Items 21-40 for the total Beck Anxiety Inventory for Youth (BAI-Y) score.~Add scores from Items 41-60 for the total Beck Depression Inventory for Youth (BDI-Y) score.~Add scores from Items 61-80 for the total Beck Anger Inventory for Youth (BANI-Y) score.~Add scores from Items 81-100 for the total Beck Disruptive Inventory for Youth (BDBI-Y) score.~Raw scores will be translated into T-scores.~T-scores for BYI are as follows:~55 or less = average~55-59 = mildly elevated~60-69 = moderately elevated~70+ = extremely elevated" (NCT03790137)
Timeframe: Month 3
Intervention | T score (Mean) | |
---|---|---|
Baseline Score | Month 3 Score | |
Treatment Group | 47.29 | 45.13 |
"The Weschler Abbreviated Scale of Intelligence (WASI-II subtests) will be administered to the first 10 patients at baseline and 84 days after the start of the first dose of study drug. Results of these cognitive tests will be compared between baseline and 84 days post initial dose.~The WASI-II measures cognitive functioning through 2 subtests, vocabulary and matrix reasoning. The raw scores on these subtests are combined to give a composite full-scale IQ (FSIQ) that is scaled to an average of 100 and standard deviation of 15.~Maximum raw scores for the subtests are as follows (higher values are considered better and minimum score on each is 0).~Vocabulary:~ages 7-11: 47 ages 12-14: 53 ages 15-25: 59~Matrix Reasoning:~ages 6-8: 24 ages 9-25: 30" (NCT03790137)
Timeframe: Month 3 (~84 days after the first dose of fenfluramine.)
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Month 3 | |
Treatment Group | 97.89 | 106.22 |
"The Weschler Intelligence Scale for Children (WISC-V) -Processing Speed subtests will be administered at baseline and 84 days after the start of the first dose of study drug (Month 3; visit 5). Results of these cognitive tests will be compared between baseline and 84 days post initial dose.~Raw scores for the coding and symbol search subtests will be used to evaluate processing speed. The maximum raw scores are as follows (the minimum score is 0 and higher scores are considered better).~Coding:~ages 6-7: 65 ages 8-16: 119~Symbol search:~ages 6-7: 45 ages 8-16: 60" (NCT03790137)
Timeframe: Month 3 (approximately 84 days after the first dose of fenfluramine)
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Month 3 | |
Treatment Group | 89.63 | 92.14 |
"The Beck Self Report Inventory will be administered at baseline, and 84 days after the first dose (Month 3; Visit 5). This questionnaire assesses self-concept, depression, anxiety, anger and disruptive behavior through a 100-item self-report.~The raw scores for subscales are calculated in the following manner:~Add scores from Items 1-20 for the total Beck Self Concept Inventory for Youth (BSCI-Y) score.~Add scores from Items 21-40 for the total Beck Anxiety Inventory for Youth (BAI-Y) score.~Add scores from Items 41-60 for the total Beck Depression Inventory for Youth (BDI-Y) score.~Add scores from Items 61-80 for the total Beck Anger Inventory for Youth (BANI-Y) score.~Add scores from Items 81-100 for the total Beck Disruptive Inventory for Youth (BDBI-Y) score.~Raw scores will be translated into T-scores.~T-scores for BYI are as follows:~55 or less = average~55-59 = mildly elevated~60-69 = moderately elevated~70+ = extremely elevated" (NCT03790137)
Timeframe: Month 3
Intervention | T score (Mean) | |
---|---|---|
Baseline Score | Month 3 Score | |
Treatment Group | 49.29 | 47.13 |
"The Beck Self Report Inventory will be administered at baseline, and 84 days after the first dose (Month 3; Visit 5). This questionnaire assesses self-concept, depression, anxiety, anger and disruptive behavior through a 100-item self-report.~The raw scores for subscales are calculated in the following manner:~Add scores from Items 1-20 for the total Beck Self Concept Inventory for Youth (BSCI-Y) score.~Add scores from Items 21-40 for the total Beck Anxiety Inventory for Youth (BAI-Y) score.~Add scores from Items 41-60 for the total Beck Depression Inventory for Youth (BDI-Y) score.~Add scores from Items 61-80 for the total Beck Anger Inventory for Youth (BANI-Y) score.~Add scores from Items 81-100 for the total Beck Disruptive Inventory for Youth (BDBI-Y) score.~Raw scores will be translated into T-scores.~T-scores for BYI are as follows:~55 or less = average~55-59 = mildly elevated~60-69 = moderately elevated~70+ = extremely elevated" (NCT03790137)
Timeframe: Month 3
Intervention | T score (Mean) | |
---|---|---|
Baseline Score | Month 3 Score | |
Treatment Group | 44.14 | 43.50 |
"The Behavioral Rating Inventory of Executive Function (BRIEF) questionnaire will be administered at baseline, and 84 days after the first dose of fenfluramine (Month 3; Visit 5). This questionnaire assesses executive function across 8 clinical scales:~Inhibit~Shift~Emotional Control~Initiate~Working Memory~Plan/Organize~Organization of Materials~Monitor~Item level scores are rated on a 3 point Likert Scale from 1-3:~Never~Sometimes~Often~The Global Executive Composite (GEC) score is the total score of all 8 clinical subscales. The item scores are summed for each scale and raw scores are converted to Tscores. The mean of the GEC score will be reported.~T scores from 60 to 64 are considered mildly elevated. T scores from 65 to 69 are considered potentially clinically elevated. T scores at or above 70 are considered clinically elevated." (NCT03790137)
Timeframe: Month 3 (approximately 84 days after the first dose of fenfluramine)
Intervention | T Score (Mean) | |
---|---|---|
Baseline Score | Month 3 Score | |
Treatment Group | 61.29 | 58.50 |
"The Quality of Life in Childhood Epilepsy Questionnaire will be administered at baseline, and 84 days after the first dose (Month 3; visit 5). This questionnaire assesses mood, social relationships, and behaviors. Results will be compared.~The QOLCE assesses quality of life across 4 domains of functioning: cognitive, emotional, social and physical. Scores range from 0-100. Composite scores are calculated as a mean across all measures." (NCT03790137)
Timeframe: Month 3 (approximately 84 days after first dose of fenfluramine)
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Month 3 | |
Treatment Group | 60.41 | 60.76 |
"The Beck Self Report Inventory will be administered at baseline, and 84 days after the first dose (Month 3; Visit 5). This questionnaire assesses self-concept, depression, anxiety, anger and disruptive behavior through a 100-item self-report.~The raw scores for subscales are calculated in the following manner:~Add scores from Items 1-20 for the total Beck Self Concept Inventory for Youth (BSCI-Y) score.~Add scores from Items 21-40 for the total Beck Anxiety Inventory for Youth (BAI-Y) score.~Add scores from Items 41-60 for the total Beck Depression Inventory for Youth (BDI-Y) score.~Add scores from Items 61-80 for the total Beck Anger Inventory for Youth (BANI-Y) score.~Add scores from Items 81-100 for the total Beck Disruptive Inventory for Youth (BDBI-Y) score.~Raw scores will be translated into T-scores.~T-scores for BYI are as follows:~55 or less = average~55-59 = mildly elevated~60-69 = moderately elevated~70+ = extremely elevated" (NCT03790137)
Timeframe: Month 3 (approximately 84 days after first dose of fenfluramine)
Intervention | T-Score (Mean) | |
---|---|---|
Baseline Score | Month 3 Score | |
Treatment Group | 44.43 | 52.88 |
The investigators will read and interpret pre- (baseline) and post-treatment (month 3) EEGs. The number of patients that experienced a photoparoxysmal response during the EEGs will be reported. (NCT03790137)
Timeframe: Month 3
Intervention | Participants (Count of Participants) | |
---|---|---|
Baseline EEG (pre-treatment) | Month 3 EEG (post-treatment) | |
Treatment Group | 5 | 3 |
2 reviews available for primidone and Convulsions, Grand Mal
Article | Year |
---|---|
Diagnosis and treatment of epilepsy: overview and general principles.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 1974 |
[Antiepileptics. 39].
Topics: Acetazolamide; Adrenocorticotropic Hormone; Aminoglutethimide; Anticonvulsants; Barbiturates; Carbam | 1969 |
5 trials available for primidone and Convulsions, Grand Mal
Article | Year |
---|---|
One drug (phenytoin) in the treatment of epilepsy.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Epilepsy; Epilepsy, Absence; Ep | 1976 |
[Therapeutic and pharmacological monitoring of individual monotherapy of epilepsy with hexamidine].
Topics: Adolescent; Adult; Anticonvulsants; Benzamidines; Dose-Response Relationship, Drug; Drug Monitoring; | 1991 |
"Anticonvulsant action" of vitamin D in epileptic patients? A controlled pilot study.
Topics: Adolescent; Adult; Alkaline Phosphatase; Anticonvulsants; Calcium; Child; Clinical Trials as Topic; | 1974 |
Ospolot (sulthiame) in epilepsy. (Preliminary report).
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Epilepsy, Tem | 1967 |
The metabolic conversion of primidone (Mysoline) to phenobarbitone in patients under long-term treatment. An attempt to estimate the independent effect of primidone.
Topics: Adult; Behavior; Clinical Trials as Topic; Drug Synergism; Electroencephalography; Epilepsy; Epileps | 1967 |
65 other studies available for primidone and Convulsions, Grand Mal
Article | Year |
---|---|
Mysoline in the treatment of recalcitrant idiopathic major epilepsy in mentally defective children.
Topics: Anticonvulsants; Child; Epilepsy; Epilepsy, Tonic-Clonic; Humans; Intellectual Disability; Primidone | 1954 |
Effect of primidone (mysoline) on grand mal attacks.
Topics: Animals; Anticonvulsants; Behavior, Animal; Epilepsy; Epilepsy, Tonic-Clonic; Primidone; Seizures | 1955 |
Treatment of epilepsy.
Topics: Acetazolamide; Anticonvulsants; Automatism; Child; Epilepsy; Epilepsy, Absence; Epilepsy, Tonic-Clon | 1963 |
PHOTIC EPILEPSY: REPORT OF AN UNUSUAL CASE AND REVIEW OF THE LITERATURE.
Topics: Adolescent; Electroencephalography; Epilepsy; Epilepsy, Reflex; Epilepsy, Tonic-Clonic; Humans; Ligh | 1964 |
[THERAPY OF CONVULSIVE DISEASES].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Barbiturates; Dexamethasone; Epilepsy; Epilepsy, Absen | 1963 |
PSYCHOMOTOR VARIANT TYPE OF SEIZURE DISCHARGE.
Topics: Adolescent; Anticonvulsants; Child; Electroencephalography; Epilepsy; Epilepsy, Absence; Epilepsy, T | 1963 |
SEIZURES INDUCED BY MOVEMENT: A FORM OF REFLEX EPILEPSY.
Topics: Adolescent; Athetosis; Cerebral Angiography; Diagnosis, Differential; Electroencephalography; Epilep | 1964 |
REPORT ON THE ANTI-EPILEPTIC ACTION OF TEGRETOL.
Topics: Acetazolamide; Adolescent; Anticonvulsants; Biomedical Research; Carbamazepine; Child; Chlordiazepox | 1964 |
[THE PROSTRATION SYNDROME. SERIOUS DANGER OF DRUG THERAPY IN EPILEPSY].
Topics: Adolescent; Anticonvulsants; Chlorpromazine; Down Syndrome; Drug Therapy; Electroencephalography; Ep | 1964 |
CERTAIN BASIC CONCEPTS CONCERNING THE TREATMENT OF THE EPILEPSIES.
Topics: Amphetamine; Anticonvulsants; Barbiturates; Child; Drug Therapy; Electroencephalography; Epilepsy; E | 1964 |
[Pharmacotherapy of epilepsy--current problems and controversies].
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; Epilepsy; Epilepsy, | 1983 |
One drug for childhood grand mal: medical audit for three-year remissions.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Epilepsy, Tonic-Clo | 1984 |
[Problems of therapeutic service in primidone therapy].
Topics: Adolescent; Drug Administration Schedule; Drug Interactions; Epilepsy, Tonic-Clonic; Female; Half-Li | 1980 |
Monotherapy or polytherapy for epilepsy?
Topics: Adolescent; Adult; Carbamazepine; Clonazepam; Drug Combinations; Drug Interactions; Drug Therapy, Co | 1981 |
Nonconvulsive status epilepticus.
Topics: Anticonvulsants; Dizziness; Electroencephalography; Emergency Service, Hospital; Epilepsy, Tonic-Clo | 1997 |
[The coincidence of visceral lupus erythematosus and epilepsy].
Topics: Adolescent; Carbamazepine; Epilepsy, Tonic-Clonic; Humans; Lupus Erythematosus, Systemic; Male; Phen | 1978 |
Simultaneous recording of pupillary hippus and EEG. Report of a case.
Topics: Adult; Alcoholism; Athetosis; Electroencephalography; Epilepsy, Tonic-Clonic; Humans; Male; Primidon | 1978 |
Serotonin metabolism with idiopathic grand mal seizures.
Topics: Blood Platelets; Calcium; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; Humans; Phenytoin; Prim | 1978 |
[Clinical significance of serum phenytoin level].
Topics: Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy, Temporal Lobe; Epileps | 1978 |
[Blood level of antiepileptic drugs and therapeutic effect in mono- and polytherapy (author's transl)].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Therapy, Comb | 1978 |
[Primary generalized epilepsy in childhood. Clinico-statistical study].
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Clonazepam; Electroencephalography; Epilepsy, | 1979 |
Medical treatment of epilepsy: Part II.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Calcium; Child; Drug Interactions; Epilepsy; Ep | 1978 |
Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy.
Topics: Acetazolamide; Adolescent; Age Factors; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy | 1975 |
Blood level estimation in phenytoin treatment of epilepsy.
Topics: Adult; Child; Chromatography, Gas; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; Humans; Phenob | 1975 |
Sensible prescribing. XI.--Juvenile and adult epilepsy.
Topics: Adolescent; Adult; Age Factors; Carbamazepine; Child; Clonazepam; Epilepsy; Epilepsy, Absence; Epile | 1975 |
[Pyknoleptic petit mal and secondary grand mal].
Topics: Adolescent; Adult; Age Factors; Barbiturates; Drug Therapy, Combination; Educational Status; Epileps | 1976 |
A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients.
Topics: Adolescent; Adult; Carbamazepine; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic; Female; Humans; M | 1976 |
Congenital malformations in four siblings of a mother taking anticonvulsant drugs.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Anticonvulsants; Child; Child, Preschool; Epil | 1976 |
Epilepsy and other seizure disorders in children: drug management.
Topics: Acetazolamide; Anticonvulsants; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epilepsy, T | 1976 |
[Effectiveness of bromide in therapy resistant epilepsy of dogs].
Topics: Animals; Bromides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Resistance; Epilepsy; | 1991 |
Low levels of gamma-aminobutyric acid in cerebrospinal fluid of dogs with epilepsy.
Topics: Animals; Dogs; Epilepsy, Tonic-Clonic; Female; gamma-Aminobutyric Acid; Male; Phenobarbital; Primido | 1986 |
Use of anticonvulsants in small animals.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Dog Diseases; Dogs; Epilepsy; Epilepsy, Tonic-Clonic; | 1986 |
Metabolism of magnesium and zinc in patients treated with antiepileptic drugs and with magnesium lactate.
Topics: Adult; Anticonvulsants; Carbamazepine; Diazepam; Epilepsy, Absence; Epilepsy, Tonic-Clonic; Erythroc | 1987 |
Withdrawal of barbiturate anticonvulsant drugs: prospective controlled study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, Partial; Epi | 1988 |
[Side effects of anticonvulsants on the peripheral nervous system and vestibulo-ocular functions].
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Epilepsy, Temporal Lobe; | 1985 |
Coarse features in epilepsy as a consequence of anticonvulsant therapy. Report of cases in two pairs of identical twins.
Topics: Acromegaly; Adult; Anticonvulsants; Carbamazepine; Child; Diazepam; Diseases in Twins; Epilepsy; Epi | 1973 |
Epilepsy.
Topics: Adrenocorticotropic Hormone; Carbamazepine; Diazepam; Drug Hypersensitivity; Drug-Related Side Effec | 1974 |
Cerebellar atrophy in epilepsy. Pneumographic and histological documentation of a case with psychosis.
Topics: Adult; Brain; Cerebellar Ataxia; Cerebral Ventriculography; Chlorpromazine; Diplopia; Electroconvuls | 1968 |
[Distinct rickets during anticonvulsant long-term therapy].
Topics: Child, Preschool; Enzyme Induction; Epilepsy, Tonic-Clonic; Female; Humans; Phenobarbital; Phenytoin | 1973 |
Dipropylacetate (Dépakine, Ergenyl) in the treatment of epilepsy.
Topics: Adolescent; Anticonvulsants; Barbiturates; Child; Child, Preschool; Drug Synergism; Electroencephalo | 1973 |
[Use of primidone in symptomatic awakening epilepsies].
Topics: Adolescent; Barbiturates; Child; Electroencephalography; Epilepsies, Partial; Epilepsy; Epilepsy, To | 1973 |
[Inheritance of spike-wave complexes and febrile seizures in three generations].
Topics: Adult; Child; Child, Preschool; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic; Ethosuximi | 1973 |
Antiepileptic therapy and rickets in children.
Topics: Adolescent; Anticonvulsants; Barbiturates; Child; Child, Preschool; Diazepam; Epilepsy; Epilepsy, To | 1973 |
The pattern of epilepsy in Uganda.
Topics: Adolescent; Adult; Age Factors; Black People; Child; Child, Preschool; Electroencephalography; Epile | 1973 |
[Haemorrhagic diathesis in a newborn child of a mother on anti-epileptic medication (author's transl)].
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; Female; Hemostatics; Huma | 1974 |
Clonazepam in the treatment of epilepsy.
Topics: Adult; Anticonvulsants; Benzodiazepinones; Chlorobenzenes; Chromatography, Gas; Drug Interactions; E | 1974 |
Prolonged trance-like stupor in epilepsy. Petit mal status-wave stupor, spaced-out status.
Topics: Adult; Behavior; Diagnosis, Differential; Diazepam; Electroencephalography; Epilepsy; Epilepsy, Abse | 1974 |
Drug treatment of convulsive disorders.
Topics: Acetazolamide; Adrenocorticotropic Hormone; Adult; Anticonvulsants; Barbiturates; Child; Diazepam; E | 1972 |
[Severe rachitic osteopathy during long-term anticonvulsant treatment].
Topics: Administration, Oral; Alkaline Phosphatase; Anticonvulsants; Biopsy; Calcium; Carbamazepine; Child; | 1973 |
Epilepsy.
Topics: Adult; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epilepsy, T | 1969 |
Drug treatment of epilepsy in childhood.
Topics: Anticonvulsants; Carbamazepine; Child; Child, Preschool; Diazepam; Epilepsy; Epilepsy, Absence; Epil | 1969 |
[Therapy of epilepsy. The causes and consequences of inadequate treatment].
Topics: Acridines; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Barbiturates; Carbamazepine; Child | 1972 |
Variation in response to anticonvulsants in a group of epileptic patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chromatography, Gas; Epilepsy, Temporal Lobe; Epilepsy, To | 1972 |
Phenylethylmalonamide (PEMA). An important metabolite of primidone.
Topics: Adult; Amides; Animals; Blood Proteins; Chromatography, Gas; Epilepsy, Temporal Lobe; Epilepsy, Toni | 1972 |
Metabolic disposition of primidone and its metabolites in epileptic subjects after single and repeated administration.
Topics: Amides; Epilepsy; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic; Humans; Phenobarbital; Primidone | 1972 |
Long term anticonvulsant therapy and cerebellar atrophy.
Topics: Adult; Avitaminosis; Cerebellar Diseases; Cranial Fossa, Posterior; Epilepsy, Tonic-Clonic; Female; | 1973 |
Epilepsy in Iceland. A clinical and epidemiological investigation.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Automobile Driving; Child; Child, Preschool; Epilepsy, Abs | 1966 |
Lymphadenopathy and megaloblastic anaemia in patient receiving primidone.
Topics: Aged; Anemia, Macrocytic; Epilepsy, Tonic-Clonic; Humans; Lymphoma; Male; Primidone; Thyroiditis, Au | 1967 |
[Treatment of epilepsy in children].
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epil | 1967 |
Controlled evaluation of primidone and diphenyllhydantoin sodium. Comparative anticonvulsant efficacy and toxicity in children.
Topics: Adolescent; Child; Child, Preschool; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic; Human | 1968 |
[On the combination treatment of epileptic attacks].
Topics: Anticonvulsants; Drug Synergism; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epilepsy, Ton | 1968 |
[On the therapy of centrocephalic epilepsy in childhood].
Topics: Adolescent; Age Factors; Anticonvulsants; Barbiturates; Child; Child Behavior; Epilepsy; Epilepsy, A | 1968 |
[Basic principles of epilepsy therapy].
Topics: Anticonvulsants; Barbiturates; Benzazepines; Carbamazepine; Epilepsy; Epilepsy, Absence; Epilepsy, T | 1970 |
[Phasic depression and epilepsy. Two polar cases].
Topics: Adult; Bipolar Disorder; Chlorprothixene; Electroencephalography; Epilepsy, Tonic-Clonic; Female; Ha | 1971 |
[Results of treatment of epilepsy in children up to 14 years of age].
Topics: Adolescent; Age Factors; Barbiturates; Child; Child, Preschool; Diazepam; Drug Synergism; Electroenc | 1971 |